Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PainReform Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PRFX
Nasdaq
2834
https://painreform.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PainReform Ltd
PainReform Announces Closing of $4 Million Public Offering
- Apr 18th, 2024 6:19 pm
PainReform Announces Pricing of $4 Million Public Offering
- Apr 16th, 2024 12:00 pm
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
- Apr 9th, 2024 2:30 pm
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
- Apr 9th, 2024 1:00 pm
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
- Apr 2nd, 2024 2:00 pm
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
- Apr 2nd, 2024 12:30 pm
PainReform Provides Year-End Business Update
- Mar 1st, 2024 1:00 pm
PainReform to Present at the Microcap Conference in Atlantic City
- Jan 22nd, 2024 1:30 pm
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
- Jan 3rd, 2024 1:30 pm
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
- Dec 26th, 2023 11:00 pm
PainReform Provides Business Update for the Third Quarter of 2023
- Nov 15th, 2023 9:05 pm
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
- Sep 11th, 2023 12:30 pm
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
- Sep 7th, 2023 2:00 pm
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
- Sep 5th, 2023 12:30 pm
PainReform Provides Business Update for the Second Quarter of 2023
- Aug 10th, 2023 8:05 pm
7 Stocks Under $10 to Buy for August
- Aug 10th, 2023 10:45 am
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
- Jul 19th, 2023 1:00 pm
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
- Jul 14th, 2023 6:35 pm
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
- Jul 12th, 2023 1:05 pm
Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely?
- Jul 3rd, 2023 1:01 pm
Scroll